SPY334.57+0.24 0.07%
DIA274.62+0.72 0.26%
IXIC11,010.98-97.09 -0.87%

Baird Upgrades Theravance Biopharma to Neutral, Lowers Price Target to $18

Baird upgrades Theravance Biopharma (NASDAQ:TBPH) from Underperform to Neutral and lowers the price target from $22 to $18.

Benzinga · -

Baird upgrades Theravance Biopharma (NASDAQ:TBPH) from Underperform to Neutral and lowers the price target from $22 to $18.